Pilot Observational Study to Determine Feasibility of a Standardized Treatment of Pulmonary Exacerb. in Patients With CF
- Conditions
- Cystic Fibrosis Pulmonary ExacerbationLung InfectionCystic Fibrosis
- Registration Number
- NCT02109822
- Lead Sponsor
- University of Washington
- Brief Summary
The goal of this research study is to better understand current treatment practices for pulmonary exacerbations (lung infections) and whether the Cystic Fibrosis National Patient Registry (CFFNPR)can be used for this type of study.
- Detailed Description
Cystic fibrosis (CF), a life-shortening genetic disease, is marked by acute episodes during which symptoms of lung infection increase and lung function decreases. These pulmonary exacerbations (PEs) are treated with varying antibiotics for varying time periods based on needs determined by individual patients, their families, and the health care providers. Cystic fibrosis pulmonary guidelines for the treatment of PE published by the Cystic Fibrosis Foundation (CFF) in 2009 provided recommendations for treatment and also identified key questions for which additional studies were needed.
Standard treatment for PE involves many facets including selection of antibiotics, duration of use, and outcomes that define treatment success. Understanding current treatment practices and measures of treatment success are needed before a study can be designed to define optimal treatment strategies.
This is a multi-center, prospective, observational study designed to prospectively follow patients with CF that are initially admitted to the hospital for treatment of a pulmonary exacerbation.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 220
- Male or female ≥12 years of age at Visit 1
- Enrolled in the CFFNPR (Patients may enroll in the Registry at Visit 1 if not previously enrolled.)
- Current hospitalization for treatment of a pulmonary exacerbation
- Planned hospital admission of at least 5 days with intravenous (IV) antibiotics at Visit 1
- Able to perform spirometry at admission and willing to perform spirometry on subsequent treatment and visit days
- Willing and able to complete symptom score daily
- Willing to return for a follow up visit at end of treatment (if necessary) and 28 days after start of IV antibiotic therapy
- Written informed consent (and assent when applicable) obtained from the participant or participant's legal representative
- Previous enrollment in this study
- Treatment with IV antibiotics in the 6 weeks prior to Visit 1
- Admission to the intensive care unit for current pulmonary exacerbation
- Pneumothorax on admission
- Current hospitalization for scheduled pulmonary clean out
- Current hospitalization for sinusitis as the primary diagnosis
- Massive hemoptysis defined as > 250 cc in a 24 hour period, or 100 cc/day over 4 consecutive days occurring within one week of Visit 1
- Current pulmonary exacerbation thought to be due to allergic bronchopulmonary aspergillosis (ABPA)
- Ongoing treatment with prednisone equivalent >10 mg/day for greater than 2 weeks initiated prior to Visit 1
- History of solid organ transplantation Currently receiving antimicrobial therapy to treat non-tuberculous mycobacterium (e.g., M. abscessus, M. avium complex)
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Feasibility of using the CFF National Patient Registry 28 days from time of start of IV antibiotic therapy. Assess feasibility using the CFF National Patient Registry as measured by the accuracy of data entry
- Secondary Outcome Measures
Name Time Method Physician and patient level clinical outcomes for their use in comparative studies of CF pulmonary exacerbations to determine the optimal treatment endpoints During hospitalization and during a period following discharge of 28 days from time of start of IV antibiotic therapy. Evaluate physician assessment of treatment response as measured by the physician treatment assessment questionnaire. Evaluate change in lung function and patient reported respiratory symptoms and quality of life in response to treatment of an acute pulmonary exacerbation.
Trial Locations
- Locations (12)
CFF Care Center & Pediatric Program Children's Hospital of Pittsburgh
🇺🇸Pittsburgh, Pennsylvania, United States
University of Washington
🇺🇸Seattle, Washington, United States
Medical University of South Carolina
🇺🇸Charleston, South Carolina, United States
CFF Adult Program University of Alabama
🇺🇸Birmingham, Alabama, United States
Johns Hopkins
🇺🇸Baltimore, Maryland, United States
National Jewish Health
🇺🇸Denver, Colorado, United States
CFF Care Center & Pediatric Program University of Wisconsin
🇺🇸Madison, Wisconsin, United States
CFF Care Center & Pediatric Program The University of Texas Southwestern Medical Center at Dallas
🇺🇸Dallas, Texas, United States
Rainbow Babies and Children's Hospital & University Hospitals Case Medical Center
🇺🇸Cleveland, Ohio, United States
CFF Care Center & Pediatric Program Seattle Children's Hospital
🇺🇸Seattle, Washington, United States
CFF Care Center Arizona Health Science Center
🇺🇸Tucson, Arizona, United States
CFF Care Center & Pediatric Program Rainbow Babies and Children's Hospita
🇺🇸Cleveland, Ohio, United States